Table 1. Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on anti-proliferative effects of TKIs.

ITK	Cell line	IC50(nM) ± SEM
Imatinib	vector	257 ± 34
	TTT	459 ± 95*
	CTT	419 ± 70*
	CGT	435 ± 84*
	CGC	732 ± 95*,§
Nilotinib	vector	13.7 ± 3.0
	TTT	21.2 ± 3.0
	CTT	18.9 ± 2.2
	CGT	19.5 ± 2,4
	CGC	25.0 ± 2.6*
Dasatinib	vector	0.33 ± 0.05
	TTT	1.31 ± 0.11***
	CTT	1.06 ± 0.04***
	CGT	1.08 ± 0.05***
	CGC	1.43 ± 0.03***, #
Ponatinib	vector	0.83 ± 0.08
	TTT	1.15 ± 0.26
	CTT	1.18 ± 0.25
	CGT	1.41 ± 0.39
	CGC	1.17 ± 0.22

Experiments were performed as in Fig. 5. Mean IC₅₀ were calculated from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001 when compared to empty vector. ^§Significantly different (p < 0.05) from all other ABCB1 variants; ^#significantly different from K562_CGT and K562_CTT.